<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01887561</url>
  </required_header>
  <id_info>
    <org_study_id>KCSG-04</org_study_id>
    <nct_id>NCT01887561</nct_id>
  </id_info>
  <brief_title>Dasatinib for Patients Achieving Complete Molecular Response for Cure D-NewS Trial</brief_title>
  <official_title>Phaseâ…¡Clinical Trial of Dasatinib for Patients With Newly Diagnosed Chronic Myeloid Leukemia in Chronic Phase and Stop Therapy After Achieving Complete Molecular Response for Cure D-NewS</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Kanto CML Study Group</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Kanto CML Study Group</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to assess whether dasatinib can be discontinued without
      occurrence of molecular relapse in patients with chronic myeloid leukemia in chronic phase in
      complete molecular remission(CMR) while on dasatinib.
    </textblock>
  </brief_summary>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Recruiting</last_known_status>
  <start_date>November 2012</start_date>
  <primary_completion_date type="Actual">December 2012</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>The overall probability of maintenance of complete molecular remission after stopping dasatinib as measured by RQ-PCR</measure>
    <time_frame>by 12 months</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>'Dasatinib affects immunological responses, as measured by flow cytometry</measure>
    <time_frame>at 3,6,12,24 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Major Molecular Response(MMR) rate measured by RQ-PCR</measure>
    <time_frame>by 1 months, then every 6 months for 2 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Complete Cytogenetic Response (CCyR) rate</measure>
    <time_frame>by 6,12 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Progression free survival (PFS)</measure>
    <time_frame>Participants were followed for at least 2 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants with Adverse Events as a Measure of Safety and Tolerability</measure>
    <time_frame>Participants were followed for at least 2 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The overall probability of maintenance of complete molecular remission after stopping dasatinib as measured by RQ-PCR</measure>
    <time_frame>by 3,6 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Molecular remission rate measured by PQ-PCR after dasatinib re-challenge in cases of molecular relapse</measure>
    <time_frame>by 12 months after molecular relapse</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Complete Molecular Response(CMR) rate measured by RQ-PCR</measure>
    <time_frame>by 1 months, then every 6 months for 2 years</time_frame>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">100</enrollment>
  <condition>Myelogenous Leukemia, Chronic, Chronic Phase</condition>
  <arm_group>
    <arm_group_label>treatment</arm_group_label>
    <arm_group_type>No Intervention</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>dasatinib</intervention_name>
    <arm_group_label>treatment</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Newly diagnosed Chronic Myeloid Leukemia in the Chronic Phase

          -  15 years old over.

          -  ECOG performance status (PS) score 0-2.

          -  Adequate organ function (hepatic, renal and lung).

          -  Signed written informed consent.

        Exclusion Criteria:

          -  A case with the double cancer of the activity.

          -  Women who are pregnant or breastfeeding.

          -  female patient who there is not intention with an appropriate sterilization, or cannot
             use it during a study entry period

          -  Patients with complications or a history of severe or uncontrolled cardiovascular
             failure following have a Myocardial infarction within 6 months have an Angina within 3
             months have a Congestive heart failure within 3 months have a QTc interval of more
             than 450msec at baseline

          -  A serious uncontrolled medical disorder that would impair the ability of the subjects
             to receive protocol therapy
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>15 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>National Disaster Medical Center</name>
      <address>
        <city>Tachikawa city</city>
        <state>Tokyo</state>
        <zip>190-0014</zip>
        <country>Japan</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Naoki Takesako</last_name>
      <phone>+81(0) 42-526-5511</phone>
      <email>ntakezak@tdmc.hosp.go.jp</email>
    </contact>
  </location>
  <location_countries>
    <country>Japan</country>
  </location_countries>
  <verification_date>June 2013</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>April 11, 2013</study_first_submitted>
  <study_first_submitted_qc>June 24, 2013</study_first_submitted_qc>
  <study_first_posted type="Estimate">June 27, 2013</study_first_posted>
  <last_update_submitted>June 24, 2013</last_update_submitted>
  <last_update_submitted_qc>June 24, 2013</last_update_submitted_qc>
  <last_update_posted type="Estimate">June 27, 2013</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Kanto CML Study Group</investigator_affiliation>
    <investigator_full_name>Naoki Takezako, M.D., Ph.D.</investigator_full_name>
    <investigator_title>Kanto CML Study Group</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Leukemia</mesh_term>
    <mesh_term>Leukemia, Myeloid</mesh_term>
    <mesh_term>Leukemia, Myelogenous, Chronic, BCR-ABL Positive</mesh_term>
    <mesh_term>Leukemia, Myeloid, Chronic-Phase</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Dasatinib</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

